Skip to main
  1. Stocks
  2. Inovio Pharmaceuticals
  3. Forecast
INO

Inovio Pharmaceuticals (INO) Stock Forecast & Price Target

Inovio Pharmaceuticals (INO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Inovio Pharmaceuticals is attractive because VOCERYQ’s FDA accelerated approval validates its DNA-medicine platform and converts a long-development story into a near-term commercial opportunity in RRP, a rare disease with meaningful unmet need. Clinical data from the Phase 1/2 RRP-001 study were compelling, with 81% of patients requiring fewer surgeries, 28% achieving complete response, and 2-year results improving to 50% complete response, supporting a differentiated profile versus surgery-heavy care and aiding adoption. Financially, 3Q26 revenue was $0.3M against a $49.2M net loss, but pro forma cash of about $139.8M after financing and warrant exercises should fund operations into late 4Q27 and support the 1Q27 launch.

Bears say

Inovio Pharmaceuticals is a clinical-stage biotechnology company with a highly speculative business model, because its DNA-encoded medicines are novel and may fail in the clinic despite the promise of its platform and INO-3107 program for HPV-6 and HPV-11-associated RRP. The completed Phase 1/2 trial does not eliminate the risk that INO-3107 may not gain approval in RRP or achieve the sales forecast implied by the company’s strategy, leaving limited visibility into durable commercial success. Fundamentally, the outlook remains negative because INOVIO will likely require additional capital to fund development and operations, a dependence that can dilute shareholders and underscore the financial fragility typical of a pre-revenue biotech.

Inovio Pharmaceuticals (INO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inovio Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Inovio Pharmaceuticals (INO) Analyst Forecast & Price Prediction

Get the latest Inovio Pharmaceuticals (INO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Inovio Pharmaceuticals (INO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inovio Pharmaceuticals (INO) Forecast

Analysts have given Inovio Pharmaceuticals (INO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Inovio Pharmaceuticals (INO) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inovio Pharmaceuticals (INO)


Inovio Pharmaceuticals (INO) Analyst Forecast & Price Prediction

Get the latest Inovio Pharmaceuticals (INO) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Inovio Pharmaceuticals (INO)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover INO stock data and trends